Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 270
Healthy volunteers: no

Brief summary:
The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At least 4 weeks will pass between periods. The study will last about 23 weeks for each participant. Participants may remain on stable dose metformin, as prescribed by their personal physician.

Detailed description:

Arms:
arm 1: Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods. arm 2: Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.

Interventions: intervention 1: LY2409021 intervention 2: Placebo intervention 3: Metformin
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered as background therapy.

Protocol document: